Early colorectal cancer Quality and rules for a good pathology report Histoprognostic factors
|
|
- Rosaline Stewart
- 6 years ago
- Views:
Transcription
1 Early colorectal cancer Quality and rules for a good pathology report Histoprognostic factors Pr Frédéric Bibeau, MD, PhD Head, Pathology department CHU de Caen, Normandy University, France ESMO preceptorship, Barcelona,
2 Quality and rules of a good pathology report Simple but rigourous
3 Reporting proforma for colorectal resection specimen
4 Useful histopronostic factors Early colorectal cancer (CRC)
5 Useful histopronostic factors Micrometastatic disease Adjuvant chemotherapy
6 Useful histopronostic factors Content - Tumour - Depth of invasion - Distant extension - Margins
7 Useful histopronostic factors - Tumour - Depth of invasion - Distant extension - Margins
8 Colorectal cancer (CRC): heterogeneous disease Different histologic types
9 CRC histologic types 90% Lieberkühnian Mucinous micropapillary adenosquamous Signet ring cells Serrated Small cells Medullary Adenocarcinoma Carcinoma
10 MSI histologic features Tumour Microenvironment Mucinous Crohn-like reaction Signet ring cells Medullary Lymphocytic infiltrate CD3+
11 CRC grading Low grade (well, moderatly differenciated) High grade (poorly/indifferenciated) modulation according to MSI status
12 Useful histopronostic factors - Tumour - Depth of invasion - Distant extension - Margins
13 ptnm classification MUCOSA Muscularis Muscosae --> SUB-MUCOSA MUSCULARIS SUB-SEROSA --> SEROSA --> pt Tis T1 T2 T3 T4 pn pm N0 : no positive lymph node (LN) N1 : 3 positive LN N2 : 4 positive LN M0 : No distant metastasis M1 : Distant metastasis TNM UICC th Classification Organe infiltration and / or visceral peritoneal perforation
14 Serosal involvement Gross examination +++
15 Serosal involvement pt4a 8 th TNM UICC 2016 classification Frankel et al. Mod Pathol 2015
16 <1mm Serosal involvement Deeper block levels Serosa involvement + reactive phenomenons pt3 pt4a 8 th TNM UICC 2016 classification Mesothelial Hyperplasia, inflammation, erosion, ulceration Frankel et al. Mod Pathol 2015
17 Serosal involvement pt4a 8 th TNM UICC 2016 classification Frankel et al. Mod Pathol 2015
18 Tumour budding optionnal Invasion front Wang LM, Am J Surg Path 2009
19 Tumour budding optionnal Tumor budding Score (0,785 mm 2 ) (Hot Spot method, X 20) HE staining 1 (Budd 1) < 5 Faible 2 (Budd 2) 5-10 Intermédiaire 3 (Budd 3) 10 Elevé Recommandations AJCC 8 th edition, Bern International Consensus Lugli et al, Modern Path 2017
20 Immune adaptative microenvironment optionnal Galon et al. Cancer Res 2007
21 Prognostic impact of immune response
22 Immune adaptative microenvironnement optionnal
23 Useful histopronostic factors - Tumour - Depth of invasion - Distant extension - Margins
24 ptnm classification MUCOSA Muscularis Muscosae --> SUB-MUCOSA MUSCULARIS SUB-SEROSA --> SEROSA --> pt Tis T1 T2 T3 T4 pn N0 : no positive lymph node (LN) N1 : 3 positive LN N2 : 4 positive LN N+ Organe infiltration and / or visceral peritoneal perforation pm M0 : No distant metastasis M1 : Distant metastasis Adjuvant chemotherapy TNM UICC th Classification
25 Distant extension: lymph nodes Recommendations > 12 But More = Better
26 Distant extension : tumour deposits Nx N0 N1 N2 N1a N1b N1c N2a N2b Lymph node status not asessable No positive regional lymph node Metastase(s) in 1-3 regional lymph node(s) 1 positive lymph node 2-3 positive regional lymph node Tumour deposits, satellites, in the sub-serosa or peri-rectal or peri-colic non peritonised tissue, without regional metastatic lymph node 4 or more positive regional lymph nodes 4-6 regional positive lymph nodes 7 regional positive lymph nodes TNM UICC th Classification
27 Distant extension : tumour deposits Pericolic or -rectal tissu location Puppa et al. Modern Pathol 2007
28 Distant extension : tumour deposits Recommendations for interprétation (F.A.Q*) - N1c only if negative lymph node - No N1c if positive lymph node - Do not add tumour deposits to positive lymph node - Do not modify T stage *Frequently Asked Question
29 Impact of «tumour deposits» N+/TD+: Next TNM classification (9 th edition)? Nagtegaal et al. J Clin Oncol :
30 Distant extension : N+ subdivision Nx N0 N1 N2 N1a N1b N1c N2a N2b Lymph node status non assessable No positive regional lymph node Metastase(s) in 1-3 regional lymph node(s) 1 positive lymph node 2-3 positive regional lymph node Tumour deposits, satellites, in the sub-serosa or peri-rectal or peri-colic non peritonised tissu without regional metastatic lymph node 4 or more positive regional lymph nodes 4-6 regional positive lymph nodes 7 regional positive lymph nodes TNM UICC th Classification 3 vs 6 months CT? Clinical trials stratification
31 Distant extension : VELIPI* Lymphatic invasion Venous invasion Perineural invasion Harris et al, Am J Surg Path 2008 Mori et al. Histopathology 2009 Liebig et al J Clin Oncol 2010 L category V category Pn1 category 8 th TNM UICC 2016 classification *Venous emboli and lymphatic and perineural invasion
32 Extra-mural venous invasion 30%: frequent underestimation? Nagtegaal et al. histopathology 2015
33 Perineural invasion OS DFS CSS Knijn et al. Am J Surg Path 2015
34 Useful histopronostic factors - Tumour - Depth of invasion - Distant extension - Margins
35 Margins Circumferential (Rectum) Distal ans proximal very rarely positive
36 Useful histopronostic factors - Tumour - Depth of invasion - Distant extension - Margins
37 Molecular profile Microsatellite instability (15%) Immunohistochemistry Molecular biology Normal DNA MSI tumour Less or supplementary nucleotides Favorable prognosis in CCR stage II
38 Molecular profile Impact of KRAS et BRAF mutations Poor prognosis in stage III CRC (MSS)* Not used as prognostic factors in 2017 Stratification for clinical trials? MSI, RAS, BRAF status for all CRC, tomorrow? *Taieb et al JAMA Oncol 2016
39 Perspectives: liquid biopsy Minimal residual disease Tie J, sci Transl Med 2016 Pierre Laurent-Puig lecture +++ ADN tumoral circulant (ADN ct) Cellule tumorale circulante (CTC) MicroARN (mirna) Adapted from Diaz et al J Clin Oncol 2014; 32:579-86
40 Perspectives - Treatment for particular stage II? - No treatment for certain stage III?
41 Take home messages
42 Useful histopronostic factors for treatment Early CRC in ptnm - Grade - VELIPI - MSI
43 Useful histopronostic factors for treatment Early CRC in 2016 Stage III - ptnm N+ (including N1c= tumour dep.) adjuvant CT - Grade - VELIPI - MSI
44 Useful histopronostic factors for treatment Early CRC in 2016 Stage II - ptnm N0 pt4 (serosa +), <12 N - Grade high (poor differenciation) - VELIPI + - MSI - Adjuvant CT (Multidisciplinary team discussion)
45 Pathology report key elements Multidisciplinary board OMS Histologic type Differenciation (Grade) Extension - Tumour (pt) - Lymph node (pn) Margins - Distal/proximal - Circumferential (Rectum) Lymphatics Veins Nerves Vasculo-lymphatic and perineural invasions
46
47 Reporting proforma for colorectal cancer
48 Translationnal research
49 Back up slides
50 Distant extension: lymph nodes Recommendations > 12 But Goldstein et al. Am J Surg Pathol 2002
51 Distant extension: lymph nodes Tougeron et al. Modern Path 2009.
52 Distant extension: lymph nodes Gross examination +++ No magic number! More = better
53 Distant extension : tumour deposits TNM 5 th edition TNM 6 th edition TNM 7, 8 th edition >3 mm Lymph node Smooth shape Lymph node No residual lymph node Tumour deposit Frankel et al. Mod Pathol 2015
54 Impact of «tumour deposits» (N1c) P< Jin et al. Am J Surg Path 2014
55 Impact of «tumour deposits» (N1c) P= Jin et al. Am J Surg Path 2014
56 Invasion front Expansive Infiltrative Svrcek et al. Cancero Dig. 2012
57 TNM Classification of Malignant Tumours - 8 th edition Changes between the 7 th and 8 th editions December 2016 We unite the cancer community to reduce the global cancer burden, to promote greater equity, and to integrate cancer control into the world health and development agenda.
58 Colon and Rectum Definition of tumour deposit clarified Tumour deposits (satellites) are discrete macroscopic or microscopic nodules of cancer in the pericolorectal adipose tissue s lymph drainage area of a primary carcinoma that are discontinuous from the primary and without histological evidence of residual lymph node or identifiable vascular or neural structures. If a vessel wall is identifiable on H&E, elastic or other stains, it should be classified as venous invasion (V1/2) or lymphatic invasion (L1). Similarly, if neural structures are identifiable, the lesion should be classified as perineural invasion (Pn1). The presence of tumour deposits does not change the primary tumour T category, but changes the node status (N) to N1c if all regional lymph nodes are negative on pathological examination
59 Colon and Rectum T and N categories Unchanged M1 M1a M1b M1c Distant metastasis Metastasis confined to one organ (liver, lung, ovary, non regional lymph node(s)) without peritoneal metastases Metastasis in more than one organ Metastasis to the peritoneum with or without other organ involvement Stage Unchanged except for Stage IVA, IVB, IVC as below Stage IV Any T Any N M1 Stage IVA Any T Any N M1a Stage IVB Any T Any N M1b Stage IVC Any T Any N M1c
60 New TNM Conclusion
61
62 Ratio tumeur/stroma Pronostic défavorable Mesker WE et al. Cell Oncol Cell Oncol. 2007;29(5): Cell Oncol. 2009;31(3): Huijbers A et al. Ann Oncol Jan;24(1):
63 Classification moléculaire CCR Instabilité chromosomique Instabilité épigénétique Instabilité microsatellitaire Voie CIN % Voie CIMP Voie MSI 20 % % Carcinome classique Tumeurs festonnées Cancer du sujet âgé Syndrome de Lynch Lieberkühnien Festonné Médullaire/ lymphocytes KRAS TP 53 BRAF
64 Profil moléculaire CCR - Corrélation morphologique? - Intégration clinique?
65 Profil moléculaire CCR Amplifications: 2,5% Mutations: 1,9% HER-2 Mutation KRAS exon 2 RAS et BRAF WT 40% RAS muté 50% MSI 15% Penault-Llorca et al.esmo 2016 Taieb et al. Jama Oncology 2016 BRAF 10% Mut KRAS ex 3, 4 Mut NRAS Courtoisie Astrid Lièvre
66 Individualisation pronostique par IHC? CDX2- CDX2+ BRAF + muté MSI BRAF + muté MSS Toon et al. Modern Pathol 2014, Dalerba et al. N Eng J Med 2015
Early colorectal cancer Quality and rules for a good pathology report Histoprognostic factors
Early colorectal cancer Quality and rules for a good pathology report Histoprognostic factors Frédéric Bibeau, MD, PhD Pathology department Biopathology unit Institut du Cancer de Montpellier France Quality
More informationColorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY
Colorectal Cancer Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth DD MM YYYY S1.02 Clinical details
More informationMicrosatellite instability and other molecular markers: how useful are they?
Microsatellite instability and other molecular markers: how useful are they? Pr Frédéric Bibeau, MD, PhD Head, Pathology department CHU de Caen, Normandy University, France ESMO preceptorship, Barcelona,
More informationStaging Challenges in Lower GI Cancers. Disclosure of Relevant Financial Relationships. AJCC 8 th edition and CAP protocol updates
Staging Challenges in Lower GI Cancers Sanjay Kakar, MD University of California, San Francisco March 05, 2017 Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education
More informationLOINC. Clinical information. RCPA code. Record if different to report header Operating surgeon name and contact details. Absent.
Complete as narrative or use the structured format below 55752-0 17.02.28593 Clinical information 22027-7 17.02.30001 Record if different to report header Operating surgeon name and contact details 52101004
More informationUpdate on staging colorectal carcinoma, the 8 th edition AJCC. General overview of staging. When is staging required? 11/1/2017
Update on staging colorectal carcinoma, the 8 th edition AJCC Dale C. Snover, MD November 3, 2017 General overview of staging Reason for uniform staging Requirements to use AJCC manual and/or CAP protocols
More informationWHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?
CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19
More informationMicrosatellite instability and other molecular markers: how usefulare they? Pr Frédéric Bibeau, MD, PhD Pathology Department CHU de Caen France
Microsatellite instability and other molecular markers: how usefulare they? Pr Frédéric Bibeau, MD, PhD Pathology Department CHU de Caen France Content - Colorectal cancer context - CRC molecular classification
More informationDisclosures. Outline. What IS tumor budding?? Tumor Budding in Colorectal Carcinoma: What, Why, and How. I have nothing to disclose
Tumor Budding in Colorectal Carcinoma: What, Why, and How Disclosures I have nothing to disclose Soo-Jin Cho, MD, PhD Assistant Professor UCSF Dept of Pathology Current Issues in Anatomic Pathology 2017
More informationWhat Pathology can tell us in the approach of localized colorectal cancer
What Pathology can tell us in the approach of localized colorectal cancer A/Prof Tony Lim Kiat Hon Department of Anatomical Pathology Singapore General Hospital ESMO 2017 Singapore Nov 1 2 Do we still
More informationGastric Cancer Histopathology Reporting Proforma
Gastric Cancer Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given name(s) Date of birth Sex Male Female Intersex/indeterminate
More informationAJCC Cancer Staging 8 th Edition
AJCC Cancer Staging 8 th Edition Colon and Rectal Cancer Staging Update Webinar George J Chang, MD, MS Deputy Chair, Department of Surgical Oncology Chief, Colon and Rectal Surgery Professor of Surgical
More informationEffect of Tumor Deposits on Overall Survival in Colorectal Cancer Patients with Regional Lymph Node Metastases
J Rural Med 2014; 9(1): 20 26 Original article Effect of Tumor Deposits on Overall Survival in Colorectal Cancer Patients with Regional Lymph Node Metastases Eiichi Yabata, Masaru Udagawa and Hiroyuki
More informationAdjuvant/neoadjuvant systemic treatment of colorectal cancer
5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico
More informationColorectal Carcinoma Reporting in 2009
Colorectal Carcinoma Reporting in 2009 Overview Colorectal carcinoma- new and confusing AJCC TNM issues Wendy L. Frankel, M.D. Vice-Chair and Director of AP Department of Pathology The Ohio State University
More informationHisto-prognostic factors what histopathology has to offer for clinical decision making
Histo-prognostic factors what histopathology has to offer for clinical decision making Daniela E. Aust Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics
More informationColon and Rectum. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition
Colon and Rectum Protocol applies to all invasive carcinomas of the colon and rectum. Carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix are excluded. Protocol revision date: January
More informationNodal staging of colorectal cancer, TNM and practical issues
Nodal staging of colorectal cancer, TNM and practical issues Gábor Cserni 1. Bács-Kiskun County Teaching Hospital, Kecskemét 2. University of Szeged, Szeged Different staging systems: A,B,C,(D) Same letters
More informationDiagnostic Difficulties Encountered Among Colorectal Polyps
Diagnostic Difficulties Encountered Among Colorectal Polyps Rhonda K. Yantiss, M.D. Professor of Pathology and Laboratory Medicine Department of Pathology and Laboratory Medicine Weill Cornell Medical
More information11/21/13 CEA: 1.7 WNL
Case Scenario 1 A 70 year-old white male presented to his primary care physician with a recent history of rectal bleeding. He was referred for imaging and a colonoscopy and was found to have adenocarcinoma.
More informationPlease Silence Your Cell Phones. Thank You
Please Silence Your Cell Phones Thank You TUMOR BUDDING IN PRE OPERATIVE BIOPSIES AND RESECTIONS Alessandro Lugli, MD Institute of Pathology and Translational Research Unit (TRU) University of Bern Bern,
More informationA916: rectum: adenocarcinoma
General facts of colorectal cancer The colon has cecum, ascending, transverse, descending and sigmoid colon sections. Cancer can start in any of the r sections or in the rectum. The wall of each of these
More informationColorectal cancer Chapelle, J Clin Oncol, 2010
Colorectal cancer Chapelle, J Clin Oncol, 2010 Early-Stage Colorectal cancer: Microsatellite instability, multigene assay & emerging molecular strategy Asit Paul, MD, PhD 11/24/15 Mr. X: A 50 yo asymptomatic
More informationGastric Cancer Staging AJCC eighth edition. Duncan McLeod Westmead Hospital, NSW
Gastric Cancer Staging AJCC eighth edition Duncan McLeod Westmead Hospital, NSW Summary of changes New clinical stage prognostic groups, ctnm Postneoadjuvant therapy pathologic stage groupings, yptnm -
More informationStaging for Residents, Nurses, and Multidisciplinary Health Care Team
Staging for Residents, Nurses, and Multidisciplinary Health Care Team Donna M. Gress, RHIT, CTR Validating science. Improving patient care. Learning Objectives Introduce the concept and history of stage
More informationRectal Cancer Cookbook Update. A. JOURET-MOURIN with the collaboration of A Hoorens,P Demetter, G De Hertogh,C Cuvelier and C Sempoux
Rectal Cancer Cookbook Update A. JOURET-MOURIN with the collaboration of A Hoorens,P Demetter, G De Hertogh,C Cuvelier and C Sempoux Prof Dr A Jouret-Mourin, Department of Pathology, UCL, St Luc, Brussels
More informationUpdate on Colorectal Cancer: Integrating the Host Immune Response 3 rd Emirates Surgical Pathology Conference 15 December 2017 Dubai, UAE
Update on Colorectal Cancer: Integrating the Host Immune Response 3 rd Emirates Surgical Pathology Conference 15 December 2017 Dubai, UAE Martine McManus, MD, FCAP Pathology & Laboratory Medicine Institute
More informationDefinition of Synoptic Reporting
Definition of Synoptic Reporting The CAP has developed this list of specific features that define synoptic reporting formatting: 1. All required cancer data from an applicable cancer protocol that are
More informationRitu Nayar, MD Professor and Vice Chair of Pathology Northwestern University, Feinberg School of Medicine Chicago, IL
Ritu Nayar, MD Professor and Vice Chair of Pathology Northwestern University, Feinberg School of Medicine Chicago, IL email: r-nayar@northwestern.edu Nothing to disclose College of American Pathologists
More informationHigh risk stage II colon cancer
High risk stage II colon cancer Joel Gingerich, MD, FRCPC Assistant Professor Medical Oncologist University of Manitoba CancerCare Manitoba Disclaimer No conflict of interests 16 October 2010 Overview
More informationJoseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital
Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital jmisdraji@partners.org Low-grade appendiceal mucinous neoplasm (LAMN) High-grade appendiceal mucinous neoplasm (HAMN) Adenocarcinoma
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More information8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank
Quiz 1 Overview 1. Beginning with the cecum, which is the correct sequence of colon subsites? a. Cecum, ascending, splenic flexure, transverse, hepatic flexure, descending, sigmoid. b. Cecum, ascending,
More informationCollaborative Stage for TNM 7 - Revised 06/30/2008 [ Schema ]
Collaborative Stage for TNM 7 - Revised 06/30/2008 [ Schema ] CS Tumor Size 000 No mass/tumor found 001-988 001-988 millimeters (code exact size in millimeters) 989 989 millimeters or larger 990 Microscopic
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationCase #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).
SOLID TUMORS WORKSHOP Cases for review Prostate Cancer Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). January 2009 PSA 4.4, 20% free; August 2009 PSA 5.2; Sept 2009
More informationWendy L Frankel. Chair and Distinguished Professor
1 Wendy L Frankel Chair and Distinguished Professor Case 1 59 y/o woman Abdominal pain No personal or family history of cancer History of colon polyps Colonoscopy Polypoid rectosigmoid mass Biopsy 3 4
More informationEarly (and not so early) colorectal cancer: The pathologist s point of view
Early (and not so early) colorectal cancer: The pathologist s point of view Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory board for
More informationNUMERATOR: Reports that include the pt category, the pn category and the histologic grade
Quality ID #100 (NQF 0392): Colorectal Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective
More informationSmall Intestine. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition
Small Intestine Protocol applies to all invasive carcinomas of the small intestine, including those with focal endocrine differentiation. Excludes carcinoid tumors, lymphomas, and stromal tumors (sarcomas).
More informationTumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma
Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given
More informationNUMERATOR: Reports that include the pt category, the pn category and the histologic grade
Quality ID #100 (NQF 0392): Colorectal Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective
More informationManagement of pt1 polyps. Maria Pellise
Management of pt1 polyps Maria Pellise Early colorectal cancer Malignant polyp Screening programmes SM Invasive adenocar cinoma Advances in diagnostic & therapeutic endoscopy pt1 polyps 0.75 5.6% of large-bowel
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationDisclosure slide I Member of advisory board for AMGEN, ROCHE, BOEHRINGER I Speaker honoraria from FALK Pharma, Pfizer, Lilly and ROCHE I Third party f
Early (and not so early) colorectal cancer: The pathologist s point of view Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory board for
More informationSignet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Published online: November 4, 2015 2015 The Author(s) Published by S. Karger AG, Basel 1662 6575/15/0083 0466$39.50/0 This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International
More informationOverview. Collecting Cancer Data: Colon 11/5/2009. Collecting Cancer Data: NAACCR Webinar Series 1. Agenda NAACCR WEBINAR SERIES
Collecting Cancer Data: Colon 11/5/2009 Collecting Cancer Data: Colon/Rectum/Appendix NAACCR 2009 2010 WEBINAR SERIES Agenda Overview Treatment MP/H Rules CSv2 2 Overview Colon/Rectum/Appendix 2009 2010
More informationThe Rodger C. Haggitt Memorial Lecture
The Rodger C. Haggitt Memorial Lecture I got an email on 4/22/14 from Hala El Zamaity inviting me to give this lecture and giving me this topic: The ever changing TNM classification and its implication
More informationHeavilyTreated mcrc..whats next?
ESMO Preceptorship Programme Gastrointestinal Cancer 20-22 October 2016,Singapore Dr Surendra Pal Chaudhary Dept of Medical Oncology Dr BR Ambedkar Instituite Rotary Cancer Hospital All India Institute
More informationHistopathology of NSCLC, IHC markers and ptnm classification
ESMO Preceptorship on Non-Small Cell Lung Cancer November 15 th & 16 th 2017 Singapore Histopathology of NSCLC, IHC markers and ptnm classification Prof Keith M Kerr Department of Pathology, Aberdeen University
More informationAJCC 7 th FAQ-1. General Rules for Staging. Question:
AJCC 7 th FAQ-1 General Rules for Staging AJCC 7th edition said if in doubt about correct T, N, or M value, use the lower (less advanced) category and if in doubt about stage grouping, choose the lower
More informationStage: The Language of Cancer
Stage: The Language of Cancer American Joint Committee on Cancer American College of Surgeons Chicago, IL Validating science. Improving patient care. No materials in this presentation may be repurposed
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationSEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING
SEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING OVERVIEW What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets Site Specific Data Items (SSDI) SEER Summary
More informationCOLORECTAL CARCINOMA
QUICK REFERENCE FOR HEALTHCARE PROVIDERS MANAGEMENT OF COLORECTAL CARCINOMA Ministry of Health Malaysia Malaysian Society of Colorectal Surgeons Malaysian Society of Gastroenterology & Hepatology Malaysian
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationColon and Rectum. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition
Colon and Rectum Protocol applies to all invasive carcinomas of the colon and rectum. Carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix are excluded. Protocol revision date: January
More informationFormula One Study. Assessment criteria of pathological parameters. Ver.2. UK Japan Joint Study for Risk Factors of Lymph Node
APPENDIX 01: Assessment criteria Formula One Study UK Japan Joint Study for Risk Factors of Lymph Node Metastasis in Submucosal Invasive (pt1) Colorectal Cancer Assessment criteria of pathological parameters
More informationMismatch repair status, inflammation and outcome in patients with primary operable colorectal cancer
Mismatch repair status, inflammation and outcome in patients with primary operable colorectal cancer Park JH, Powell AG, Roxburgh CSD, Richards CH, Horgan PG, McMillan DC, Edwards J James Park Clinical
More informationGreater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy
Greater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy Authors: Dr Gordon Armstrong, Dr Sue Pritchard 1. General Comments 1.1 Cancer reporting: Biopsies
More informationMSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany
MSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory boards for AMGEN, ROCHE I Speaker
More informationLUNG STAGING FORM LATERALITY: LEFT RIGHT BILATERAL
LUNG STAGING FORM LATERALITY: LEFT RIGHT BILATERAL ( ) Tx Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging
More informationCODING STAGE: TNM AND OTHER STAGING SYSTEMS. Liesbet Van Eycken Otto Visser
CODING STAGE: TNM AND OTHER STAGING SYSTEMS Liesbet Van Eycken Otto Visser OVERVIEW PART I Introduction What is stage? Why stage? History and publications of TNM Classification Clinical and pathologic
More informationEnrollment Form: Pancreas
Tissue Source Site (TSS) Name: TSS Identifier: _ TSS Unique Patient #: Completed By: Completion Date (MM/DD/YYYY): Form Notes: An Enrollment Form should be completed for each TCGA qualified case upon qualification
More informationMolecular markers in colorectal cancer. Wolfram Jochum
Molecular markers in colorectal cancer Wolfram Jochum Biomarkers in cancer Patient characteristics Tumor tissue Normal cells Serum Body fluids Predisposition Diagnostic marker Specific diagnosis Prognostic
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More information3/23/2017. Disclosure of Relevant Financial Relationships. Pathologic Staging Updates in Lung Cancer T STAGE OUTLINE SURVIVAL ACCORDING TO SIZE ONLY
Pathologic Staging Updates in Lung Cancer Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME
More informationControversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE
Controversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE Neoadjuvant Chemotherapy Indications: Management of locally advanced invasive breast cancers including inflammatory breast
More information2014/2015 FCDS Educational Webcast Series
2014/2015 FCDS Educational Webcast Series February 19, 2015 Steven Peace, CTR 2015 Update; Background, Anatomy, Risk Factors, Screening Guidelines, MPH Rules Review AJCC TNM 7 th ed, SS2000, CSv02.05 and
More informationProtocol applies to melanoma of cutaneous surfaces only.
Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC
More informationCOLORECTAL CANCER: PROGNOSTIC VALUES
& COLORECTAL CANCER: PROGNOSTIC VALUES Suzana Manxhuka-Kerliu¹*, Skender Telaku², Halil Ahmetaj³, Arijeta Baruti¹, Sadushe Loxha¹, Agron Kerliu³ ¹ Institute of Pathology, Faculty of Medicine, University
More informationSTAGE CATEGORY DEFINITIONS
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
More informationL impatto dell imaging sulla definizione della strategia terapeutica
GISCoR L impatto dell imaging sulla definizione della strategia terapeutica M. Galeandro U.C. Radioterapia Oncologica ASMN-IRCCS Reggio Emilia 14 Novembre 2014 Rectal Cancer TNM AJCC-7 th edition 2010
More informationACRIN 6666 Therapeutic Surgery Form
S1 ACRIN 6666 Therapeutic Surgery Form 6666 Instructions: Complete a separate S1 form for each separate area of each breast excised with the intent to treat a cancer (e.g. each lumpectomy or mastectomy).
More information47. Melanoma of the Skin
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationThe pathological phenotype of colon cancer with microsatellite instability
Dan Med J 63/2 February 2016 danish medical JOURNAL 1 The pathological phenotype of colon cancer with microsatellite instability Helene Schou Andersen 1, 2, Claus Anders Bertelsen 1, Rikke Henriksen 1,
More informationPATHOLOGIC FACTORS PROGNOSTIC OF SURVIVAL IN PATIENTS WITH GI TRACT AND PANCREATIC CARCINOMA TREATED WITH NEOADJUVANT THERAPY
PATHOLOGIC FACTORS PROGNOSTIC OF SURVIVAL IN PATIENTS WITH GI TRACT AND PANCREATIC CARCINOMA TREATED WITH NEOADJUVANT THERAPY Jeannelyn S. Estrella, MD Department of Pathology The UT MD Anderson Cancer
More informationChapter 2 Staging of Breast Cancer
Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination
More informationUpdate on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD
Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational and Molecular Pathology
More informationCOLORECTAL CANCER STAGING in 2010
COLORECTAL CANCER STAGING in 2010 Robert A. Halvorsen, MD, FACR MCV Hospitals / VCU Medical Center Richmond, Virginia I do not have any relevant financial relationships with any commercial interests COLON
More informationOFCCR CLINICAL DIAGNOSIS AND TREATMENT FORM
OFCCR CLINICAL DIAGNOSIS AND TREATMENT FORM Name: _, OFCCR # _ OCGN # _ OCR Group # _ HIN# Sex: MALE FEMALE UNKNOWN Date of Birth: DD MMM YYYY BASELINE DIAGNOSIS & TREATMENT 1. Place of Diagnosis: Name
More informationSeventh Edition Staging 2017 Colorectum. Overview. This webinar is sponsored by. the Centers for Disease Control and Prevention.
Seventh Edition Staging 2017 Colorectum Donna M. Gress, RHIT, CTR Validating science. Improving patient care. No materials in this presentation may be repurposed in print or online without the express
More information05/07/2018. Organisation. The English screening programme what is happening? Organisation. Bowel cancer screening in the UK is:
Organisation The English screening programme what is happening? Phil Quirke Lead Pathologist Bowel Cancer Screening PHE England Bowel Cancer Screening Pathology Committee Started 2006 with roll out 4 devolved
More informationProcedures Needle Biopsy Transurethral Prostatic Resection Suprapubic or Retropubic Enucleation (Subtotal Prostatectomy) Radical Prostatectomy
Prostate Gland Protocol applies to invasive carcinomas of the prostate gland. Protocol web posting date: July 2006 Protocol effective date: April 2007 Based on AJCC/UICC TNM, 6 th edition Procedures Needle
More informationCase presentation. Eran Zittan. MD Mount Sinai Hospital, Toronto, Canada. Emek Medical Center, Afula, Israel. March, 2016
Case presentation Eran Zittan. MD Mount Sinai Hospital, Toronto, Canada. Emek Medical Center, Afula, Israel. March, 2016 60 y/o man with long standing UC+PSC. Last 10 years on clinical and endoscopic remission.
More informationMolecular subtyping: how useful is it?
Molecular subtyping: how useful is it? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics at the NCT-Partner Site Dresden CMTD Disclosure
More informationIs Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer?
Is Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer? Lee H, Park JY, Youn S, Kwon W, Heo JS, Choi SH, Choi DW Department of Surgery, Samsung Medical Center Sungkyunkwan
More informationIMAGING GUIDELINES - COLORECTAL CANCER
IMAGING GUIDELINES - COLORECTAL CANCER DIAGNOSIS The majority of colorectal cancers are diagnosed on colonoscopy, with some being diagnosed on Ba enema, ultrasound or CT. STAGING CT chest, abdomen and
More informationINMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO. CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS?
INMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS? V. Alonso Servicio de Oncologia Medica H. U. Miguel Servet Zaragoza MSI-H mcrc Clinical and Pathological
More information6. Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationProtocol for the Examination of Specimens from Patients with Primary Carcinoma of the Colon and Rectum
Protocol for the Examination of Specimens from Patients with Primary Carcinoma of the Colon and Rectum Well-differentiated neuroendocrine neoplasms (carcinoid tumors) are not included. This modified NB
More informationL ARYNX S TAGING F ORM
CLI N I CA L Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX T0 Tis a b L ARYNX S TAGING F ORM LATERALITY: TUMOR SIZE: left
More informationThe 8th Edition of the TNM Classification for Lung Cancer Background, Innovations and Implications for Clinical Practice
The 8th Edition of the TNM Classification for Lung Cancer Background, Innovations and Implications for Clinical Practice University of Torino Lecture 28th June 2017 Torino, Italy Ramón Rami-Porta Thoracic
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationCaring for a Patient with Colorectal Cancer. Objectives. Poll question. UNC Cancer Network Presented on 10/15/18. For Educational Use Only 1
Caring for a Patient with Colorectal Cancer Tammy Triglianos RN, APRN-BC, AOCNP Nurse Practitioner, GI Oncology 10/15/2018 Objectives Describe common signs and symptoms of colorectal cancer Understand
More information8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC
8th Edition of the TNM Classification for Lung Cancer Proposed by the IASLC Introduction Stage classification - provides consistency in nomenclature - improves understanding of anatomic extent of tumour
More informationProtocol for the Examination of Specimens From Patients With Primary Carcinoma of the Colon and Rectum
Protocol for the Examination of Specimens From Patients With Primary Carcinoma of the Colon and Rectum Well-differentiated neuroendocrine neoplasms (carcinoid tumors) are not included. Based on AJCC/UICC
More informationGreater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14
Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14 Contents 14. Neuroendocrine Tumours 161 14.1. Diagnostic algorithm
More information